BoneKEy Reports | BoneKEy Watch

JAG1 acts through Notch signaling to regulate human bone mass



DOI:10.1038/bonekey.2013.84

Alagille Syndrome (ALGS), an autosomal dominant genetic disorder characterized by liver choleostasis, low bone mass and poor fracture healing, is associated with mutations in Jagged-1 (JAG1), a gene that encodes a single transmembrane glycoprotein expressed in mammalian cell membranes, where it acts as a Notch ligand receptor. In an effort to explain why Jag1 mutations lead to the morbidity observed, Zhu et al. conducted in vitro studies using primary mouse and human mesenchymal stem cells (MSCs) to determine the impact of Jag1-activated Notch signaling on osteoblastogenesis.

Overall, the results suggested that Jag1 acts through canonical Notch signaling in association with PKCδ signaling to stimulate differentiation of osteoblasts. Some discrepancies were noted in the effect that Jag1 had on mouse MSCs (mMSCs) and human MSCs (hMSCs); plating hMSCs on Jag1 leads to the induction of osteoblast differentiation but the same experiment using mMSCs caused inhibition of osteoblastogenesis.

Editor’s comment: The observation that Jag1 causes release of the Notch-2 intracellular domain, which then interacts with Jag1-activated PKCδ to induce MSCs to differentiate into osteoblasts, provides a possible explanation for the genetic basis of ALGS. The study also highlights differences in murine and human MSCs, something that research into ALGS etiology should take into account.


Creative Commons License This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 United States License.